Arvinas, INC 10-K annual reports

Arvinas, a clinical-stage biotechnology company, reports its 2025 annual results, highlighting the FDA's acceptance of its vepdegestrant NDA and progress across its PROTAC degrader pipeline, alongside strategic workforce reductions and a shift in vepdegestrant commercialization strategy.

Arvinas, Inc.'s 10-K filing reveals a year of strategic shifts, clinical trial progress, and financial recalibration in the biopharmaceutical landscape.

Arvinas, Inc. reported its full year 2023 results, highlighting progress in its clinical programs and a strategic shift to prioritize the ARV-766 Phase 3 trial over bavdegalutamide.